Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Application Number 10595386 Filing Date 2004-10-11 First Named Inventor Roger Butlin Art Unit 1751 Examiner Name Not yet assigned Attorney Docket Number 101243-1P US

| | | | | U.S.I | PATENTS | Remove |
|----------------------|------------|--------------------------|---------------------------|---------------------|---|--|
| Examiner Initial* | Cite No | Patent Number | Kind Code ¹ | Issue Date | Name of Patentee or Applicant of cited Document | Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear |
| | 1 | 6110949 | А | 2000-08-29 | Villhauer, E.B et al. | |
| | 2 | 6107317 | А | 2000-08-22 | Villhauer, E.B et al | |
| | 3 | 6548481 | B1 | 2003-04-15 | Demuth, H et al | |
| | 4 | 7229969 | B2 | 2007-06-12 | Ansorge, S et al | |
| If you wis | h to ac | dd additional U.S. Paten | t citatio | n information pl | ease click the Add button. | Add |
| | | | U.S.P | ATENT APPLI | CATION PUBLICATIONS | Remove |
| Examiner Initial* | Cite No | Publication Number | Kind Code ¹ | Publication Date | Name of Patentee or Applicant of cited Document | Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear |
| | 1 | 20050014699 | A1 | 2005-01-20 | Ansorge, S et al | |
| | 2 | 20060211602 | A1 | 2006-09-21 | Ansorge, S et al | |

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

| Application Number | | 10595386 | | |
|----------------------------|--|--------------|--|--|
| Filing Date | | 2004-10-11 | | |
| First Named Inventor Roger | | r Butlin | | |
| Art Unit | | 1751 | | |
| Examiner Name Not ye | | et assigned | | |
| Attorney Docket Number | | 101243-1P US | | |

| | 3 | 20040147434 | A1 | 2004-07 | '-29 | Ansorge, S et | al | | | | |
|--|------------|---|------------------------------|-----------|---------------------------|---------------------|--|--------|-----------|-------------|----|
| If you wis | h to ac | dd additional U.S. Publi | shed Ap | plication | citatio | n information p | lease click the Add | button | ı. Add | | |
| If you wish to add additional U.S. Published Application citation information please click the Add butto FOREIGN PATENT DOCUMENTS | | | | | | | | | Remove | | |
| Examiner Initial* | Cite No | Foreign Document Number ³ | Country Code ² | | Kind Code ⁴ | Publication Date | Name of Patentee Applicant of cited Document | or \ | where Rel | or Relevant | T5 |
| | 1 | 03/031410 | WO | | A1 | 2003-04-17 | Neurocrine Bioscier Inc. | ices, | | | |
| | 2 | 03/000181 | wo | | A2 | 2003-01-03 | Merck & Co, Inc. | | | | |
| | 3 | 05/123685 | WO | | A1 | 2005-12-29 | AstraZeneca AB AstraZeneca UK Lin | nited | | | |
| | 4 | 04/007468 | WO | | A1 | 2004-01-22 | Merck & Co, Inc. | | | | |
| | 5 | 98/19998 | WO | | A2 | 1998-05-14 | Novartis AG | | | | |
| | 6 | 00/34241 | WO | | A1 | 2000-06-15 | Novartis AG Novartis-Erfindunge | en | | | |
| | 7 | 01/96295 | WO | | A2 | 2001-12-20 | Novartis AG Novartis-Erfindunge | en | | | |
| | 8 | 01/40180 | WO | | A2 | 2001-06-07 | Ferring BV | | | | |

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

| Application Number | | 10595386 | | |
|----------------------------|--|--------------|--|--|
| Filing Date | | 2004-10-11 | | |
| First Named Inventor Roger | | r Butlin | | |
| Art Unit | | 1751 | | |
| Examiner Name Not ye | | et assigned | | |
| Attorney Docket Number | | 101243-1P US | | |

| | 9 | 01/68603 | WO | A2 | 2001-09-20 | Bristol-Myers Squibb Co. | |
|--|----|-----------|----------|---------|------------|----------------------------------|--|
| | 10 | 03/000180 | WO | A2 | 2003-01-03 | Merck & Co, Inc. | |
| | 11 | 03/004498 | wo | A1 | 2003-01-16 | Merck & Co, Inc. | |
| | 12 | 03/082817 | WO | A2 | 2003-10-09 | Merck & Co, Inc. | |
| | 13 | 04/043940 | WO | A1 | 2004-05-27 | Merck & Co, Inc. | |
| | 14 | 04/037169 | WO | A2 | 2004-05-06 | Merck & Co, Inc. | |
| | 15 | 02/076450 | wo | A1 | 2002-10-03 | Merck & Co, Inc | |
| | 16 | 06/040625 | wo | A1 | 2006-04-20 | Glenmark Pharmaceuticals S.A. | |
| | 17 | 05/095343 | wo | A1 | 2005-10-13 | Graffinity Pharmaceuticals AG | |
| If you wish to add additional Foreign Patent Document citation information please click the Add button Add | | | | | | | |
| | | | NON-PATE | NT LITE | RATURE DO | CUMENTS Remove | |
| Examiner Initials* Cite No Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published. | | | | | | | |

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

| Application Number | | 10595386 | | |
|----------------------------|--|--------------|--|--|
| Filing Date | | 2004-10-11 | | |
| First Named Inventor Roger | | r Butlin | | |
| Art Unit | | 1751 | | |
| Examiner Name Not you | | et assigned | | |
| Attorney Docket Number | | 101243-1P US | | |

| | 1 | YAMADA, M et al, "A Potent Dipeptide Inhibitor of Dipeptidyl Peptidase IV", Bioorganic & Medicinal Chemistry Letters, 1998, pages 1537-1540, Vol 8(12). | | | | | | |
|---|--|--|---|------------|--|--|--|--|
| | 2 | LENDECKEL, U et al, "Synergistic Action of DPIV and APN in the Regulation of T Cell Function", Advances in Exptl Medicine and Biology, 2003, pages 123-131, Vol 524. | | | | | | |
| | 3 IKEMOTO, N et al, "Highly Diastereoselective Heterogeneously Catalyzed Hydrogenation of Enamines for the Synthesis of Chiral beta-Amino Acid Derivatives", J. Am. Chem. Soc, 20, pages 3048-3049, Vol 126. | | | | | | | |
| | 4 | AUGUSTYNS, K et al, The Unique Properties of Dipeptidyl-peptidase IV (DPP IV / CD26) and the Therapeutic Potential of DPP IV Inhibitors", Current Medicinal Chemistry, 1999, pages 311-327, Vol 6. | | | | | | |
| | 5 | DEACON, C, "Dipeptidyl peptidase IV inhibitors: A promising new therapeutic approach for the management of type 2 diabetes", The International Journal of Biochemistry and Cell Biology", 2006, pages 831-844, Vol 38. | | | | | | |
| If you wis | h to a | dd add | ditional non-patent literature document citation information please click the Add | button Add | | | | |
| | | | EXAMINER SIGNATURE | | | | | |
| Examiner | Signa | iture | Date Considered | | | | | |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | | |
| ¹ See Kind Codes of USPTO Patent Documents at <u>www.USPTO.GOV</u> or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached. | | | | | | | | |